Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

Clinical trial NCT02707601 · COMPLETED

Trial details

NCT number: NCT02707601
Sponsor: Gilead Sciences
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HIV-1 Infection HCV Infection

Start date: 2016-04-01
Primary completion: 2017-09-14
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.